RESEARCH ARTICLE

Pemetrexed as a Component of
line agent in treating patients with lung adenocarcinoma. Pemetrexed (PEM) is an effective and well tolerated chemotherapeutic agent. Based on previous studies, it is considered that PEM is proper for patients who were pathologically diagnosed with lung adenocarcinoma (Rodrigues-Pereira et al., 2011) . The tolerability of PEM is good, thus is recommended for patients with advanced NSCLC and adenocarcinoma, regardless of whether TS, GARFT, and DHFR is over-expressed. Considering general characteristics of patients with advanced NSCLC and the pharmacokinetics and well tolerability of PEM, we hypothesize that pemetrexed as a component of first-, second-and third line chemotherapy could be a reasonable regimen in treating patients with lung adenocarcinoma.
Materials and Methods
Patient eligibility
Eligible patients should be histologically confirmed adenocarcinoma of lung with clinical evidence of metastatic disease. Other eligible criteria include: age≥18 years; adequate bone marrow (platelets≥100×109 cells/l, absolute neutrophil count≥1.5×109 cells/l), hepatic (total bilirubin ≤ 2×the upper limit of normal; aspartatetransaminase ≤ 3×the upper limit of normal or ≤ 5× the upper limit of normal if metastatic disease was present in the liver) and calculated creatinine clearance ≥ 45 ml/min, using the modified Cockcroft and Gault calculated creatinine clearance formula; a life expectancy of ≥ 3 months; sign an informed consent before chemotherapy. Complete patient histories, physical examinations, complete blood cell counts, chemistries (aspartate aminotransferase, total bilirubin, creatinine, albumin), calculated creatinine clearance were performed at baseline prior to each course of treatment. Complete blood cell count was repeated weekly. Radiological studies (roentgenograms,computed axial tomographic scans or magnetic resonance imaging) were performed at baseline and after every two cycles of therapy to assess tumor response. CR was defined as complete disappearance of all measurable disease. Partial response (PR) was defined as at least 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. Progression was defined as 50% increase or an increase of 10 cm 2 (whichever is smaller) in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) or appearance of any new lesion, or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). Stable disease (SD) was documented when there was persistence of disease without meeting the criteria for progression, PR or CR.
Treatment
Pemetrexed 500 mg/m 2 was given intravenously on day 1, premedication was conducted, and repeated every 3 weeks: 400 μg of folic acid was given orally daily and 1000 μg of vitamin B12 was given intramuscularly every 9 weeks starting 7 days prior to the first dose and until 3 weeks after the last dose of pemetrexed; 4.5 mg of dexamethasone was given orally every 12 h on the day before, day of and the day after pemetrexed; and another chemotherapieutic agent (e.g., a platinum, paclitaxel, docetaxel, ifosfamide, irinotecan, etoposide, etc.) every 3 weeks until disease progression, or intolerable toxicity. Then, the patients were changed to second line chemotherapy that was based on pemetrexed 500 mg/m 2 and another chemotherapieutic agent different from the first line until disease progression, or intolerable toxicity. When third line chemotherapy was needed, pemetrexed 500 mg/m 2 and a chemotherapieutic agent different from first and second line was combined until disease progression. Antiemetics were given with chemotherapy on days 1. All toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (version2.0) (National Cancer Institute, 1998).
Research experience
We have enough experience in conducting medical researches, and have published some results elsewhere Yan et al., 2011; Zhang et al., 2011; Gong et al., 2012; Liu et al., 2012; Gu et al., 2013; Shu et al., 2012; Zhan et al., 2012; Zhan et al., 2012; Xu et al., 2012; Xu et al., 2012; Yu et al., 2012; Zhang, et al., 2012; Zhang et al., 2012; Chen et al., 2013; Dai et al., 2013; Deng et al., 2013; Huang et al., 2013; Lu et al., 2013; Wei et al., 2013; Wu et al., 2013; Yang et al., 2013; Yin et al., 2013; Yin et al., 2013) .
Results
Patients
A total of 15 patients were enrolled from January 2010 to September 2013. All patients received at least one systemic chemotherapy. All patients had adenocarcinoma of the lung. General characteristics of patients were listed in Table 1 . Fifteen patients received pemetrexed based (Table 2) .
Efficacy
Fifteen patients completed at least 2 cycles of chemotherapy on first line chemotherapy, and were evaluated according to study protocol. Overall, 5 patients (33.3%) achieved PR, while 6 patients (40.0%) remained stable, no CR on first line; and 1 PR (7.7%), 5 stable (38.5%)were recorded when pemetrexed was ordered in second line; 5 patients (41.7%) got stable after pemetrexed was combined in third line; no complete response was observed (Table 2) .
Toxicity
Main side effects were grade 1 to 2 neutrophil suppression and thrombocytopenia. Other toxicities included elevated transaminase and oral mucositis, no treatment related death occurred (Table 3) .
Discussion
According to WHO statistics, the incidence and motality rate of lung cancer increases year by year. And in China, more than 75% of patients with non-small cell lung cancer (NSCLC) present with locally advanced (stage IIIB) or metastatic (stage IV) disease at diagnosis (Zhou et al., 2011) . For patients in this setting, platinum-based chemotherapy is recommended as first-line treatment according to current guideline (Pfister et al., 2003) . Some studys showed non-inferior efficacy and better tolerability for PEM plus cisplatin compared with cisplatin plus other chemotherapeutic agents eg. gemcitabine or docetaxel especially for patients with adenocarcinoma (Reck et al., 2009; Scagliotti et al., 2009; Klein et al., 2010) . PEM is an antifolate that inhibits multiple enzymes involved in purine and pyrimidine synthesis. The mechanism of action consists of the inhibition of three key enzymes in the folate metabolic pathway, including thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT) (Giovannetti et al., 2005) . This mechanism leads to depletion of fully reduced folate, ultimately resulting in disruption of nucleotide synthesis for both pyrimidines and purines. Pemetrexed, once in the cell, is an excellent substrate for polylpolyglutamate synthetase, leading to extensive intracellular polyglutamate derivates that are more potent inhibitors of the described enzymes. Polyglutamated pemetrexed is retained intracellularly longer than the parent compound, resulting in more prolonged cytotoxic effects (Esteban et al., 2009) . It is reported that resistance to PEM is correlated with high pre-treatment TS, GARFT, and DHFR expression in NSCLC cell (Eismann et al., 2006) . TS expression is regarded as the most meaningful predictor for sensitivity or resistance to PEM in fresh tumor tissue. But for patients with advanced NSCLC, no enough tumor tissue is available for the detection of TS, GARFT, and DHFR expression. And limited by the condition of experiment in different hospitals and regions, the test result cannot be in full compliance with the actual situation. Thus at present, PEM is given to patients with advanced NSCLC, regardless of whether TS, GARFT, and DHFR is over-expressed. And in the field of maintenance therapy for advanced NSCLC, in line with the evidence currently available, it represents a treatment option. In real practice, maintenance therapy is recommended to patients without disease progression or persistent chemotherapy-induced toxicities after several cycles of first-line chemotherapy, however, with good performance status. Two different strategies (switch or continuation maintenance) are available. The hazard ratio for PFS is in the range of 0.6 to 0.7 in most of the trials for both strategies. OS is only significantly improved in the SATURN (Cappuzzo et al., 2010) and JMEN (Ciuleanu et al., 2009 ) switchmaintenance trials, and in the PARAMOUNT trial (Paz- Ares et al., 2012) with the continuation strategy. These were the only three trials with a reasonable size (539 to 889 patients) to enable adequately powered comparisons. No powered comparative trials of maintenance with different chemotherapy drugs or targeted agents have been conducted, thus, no conclusive data are available yet about the potential advantage of any given therapy. The potential advantages and disadvantages, including toxicities, of continuation or switch maintenance is not sure. The PARAMOUNT trial revealed that pemetrexed maintenance therapy could improve efficacy over placebo following four courses of cisplatin/pemetrexed (Paz- Ares et al., 2011) . The primary objective of this study, PFS, was improved in the pemetrexed maintenance arm compared with placebo (4.1 vs. 2.8 months, HR 0.62), and OS was also significantly improved (13.9 vs. 11 months, HR 0.78) (Paz- Ares et al., 2012) .
Recent placebo-controlled trials evaluated the role of pemetrexed as maintenance therapy for patients with advanced NSCLC following disease control with four cycles of platinum-based therapy and suggested that pemetrexed maintenance significantly improved PFS (4.0 vs. 2.0 months; HR 0.60) and OS (13.4 vs. 10.6 months; HR 0.79) (Ciuleanu et al., 2009; Cappuzzo et al., 2010) . Prolonging treatment duration has shown to prolong PFS, without a clinically significant effect on survival, at the cost of relevant toxicity, particularly with platinum agents and taxanes (Lima et al., 2009) . This is the reason why we try to develop a regimen that is tolerable to patient at this point. However, no study focused on pemetrexed as a basement of combined treatment from first to second and third line chemotherapy. Our study demonstrated that 5 patients (33.3%) achieved PR, while 6 patients (40.0%) remained stable, on first line; and 1 PR (7.7%), 5 stable (38.5%)were recorded when pemetrexed was ordered in second line; 5 patients (41.7%) got stable after pemetrexed was combined in third line. Main side effects were Grade 1 to 2 neutrophil suppression and thrombocytopenia. Other toxicities included elevated transaminase and oral mucositis, no treatment related death occurred.
In conclusion, our study suggested that pemetrexed continuously as a basement agent from first-, second-to third line chemotherapy is mildly effective in treating patients with metastatic lung adenocarcinoma with tolerable toxicity.
